Reflecting On Real Estate Services Stocks' Q1 Earnings: RE/MAX (NYSE:RMAX)
Technology has been a double-edged sword in real estate services. On the one hand, internet listings are effective at disseminating information far and wide, casting a wide net for buyers and sellers to increase the chances of transactions. On the other hand, digitization in the real estate market could potentially disintermediate key players like agents who use information asymmetries to their advantage.
The 13 real estate services stocks we track reported a strong Q1. As a group, revenues beat analysts' consensus estimates by 2% while next quarter's revenue guidance was 0.8% below.
While some real estate services stocks have fared somewhat better than others, they have collectively declined. On average, share prices are down 1.8% since the latest earnings results.
Short for Real Estate Maximums, RE/MAX (NYSE:RMAX) operates a real estate franchise network spanning over 100 countries and territories.
RE/MAX reported revenues of $74.47 million, down 4.9% year on year. This print exceeded analysts' expectations by 1.3%. Overall, it was a satisfactory quarter for the company with a solid beat of analysts' EPS estimates but EBITDA guidance for next quarter missing analysts' expectations.
"For the fourth consecutive quarter, our company delivered solid profit and margin performance," said Erik Carlson, RE/MAX Holdings Chief Executive Officer.
RE/MAX pulled off the highest full-year guidance raise of the whole group. The results were likely priced in, however, and the stock is flat since reporting. It currently trades at $7.75.
Is now the time to buy RE/MAX? Access our full analysis of the earnings results here, it's free.
Founded in Toronto, Canada in 2014, The Real Brokerage (NASDAQ:REAX) is a technology-driven real estate brokerage firm combining a tech-centric model with an agent-centric philosophy.
The Real Brokerage reported revenues of $354 million, up 76.3% year on year, outperforming analysts' expectations by 6.3%. The business had a stunning quarter with a solid beat of analysts' EPS estimates and an impressive beat of analysts' EBITDA estimates.
The Real Brokerage achieved the fastest revenue growth among its peers. Although it had a fine quarter compared its peers, the market seems unhappy with the results as the stock is down 7.6% since reporting. It currently trades at $4.12.
Is now the time to buy The Real Brokerage? Access our full analysis of the earnings results here, it's free.
Founded in 2009, eXp World (NASDAQ:EXPI) is a real estate company known for its virtual, cloud-based approach to real estate brokerage.
eXp World reported revenues of $954.9 million, up 1.3% year on year, falling short of analysts' expectations by 4%. It was a disappointing quarter as it posted a significant miss of analysts' adjusted operating income estimates.
As expected, the stock is down 1.7% since the results and currently trades at $8.52.
Read our full analysis of eXp World's results here.
Founded in 1999 through the merger of Jones Lang Wootton and LaSalle Partners, JLL (NYSE:JLL) is a company specializing in real estate advisory and investment management services.
JLL reported revenues of $5.75 billion, up 12.1% year on year. This result topped analysts' expectations by 4.1%. Aside from that, it was a mixed quarter as it also logged a decent beat of analysts' EBITDA estimates.
The stock is down 3% since reporting and currently trades at $222.70.
Read our full, actionable report on JLL here, it's free.
Founded by a former medical school student, electrical engineer, and Amazon data engineer, Redfin (NASDAQ:RDFN) is a real estate company offering brokerage services through an online platform.
Redfin reported revenues of $221 million, down 2% year on year. This number met analysts' expectations. Overall, it was a strong quarter as it also logged an impressive beat of analysts' EPS estimates and a solid beat of analysts' adjusted operating income estimates.
The stock is up 13.2% since reporting and currently trades at $10.
Read our full, actionable report on Redfin here, it's free.
Thanks to the Fed's series of rate hikes in 2022 and 2023, inflation has cooled significantly from its post-pandemic highs, drawing closer to the 2% goal. This disinflation has occurred without severely impacting economic growth, suggesting the success of a soft landing. The stock market thrived in 2024, spurred by recent rate cuts (0.5% in September and 0.25% in November), and a notable surge followed Donald Trump's presidential election win in November, propelling indices to historic highs. Nonetheless, the outlook for 2025 remains clouded by potential trade policy changes and corporate tax discussions, which could impact business confidence and growth. The path forward holds both optimism and caution as new policies take shape.
Want to invest in winners with rock-solid fundamentals? Check out our Top 6 Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
Sabre (SABR) Stock Trades Up, Here Is Why
What Happened? Shares of travel technology company Sabre (NASDAQ:SABR) jumped 3.4% in the morning session after investment firm Bernstein upgraded the travel technology company to 'Outperform' from 'Market Perform', suggesting the market has become too pessimistic on its outlook. The upgrade comes even as Bernstein lowered its price target on the stock to $3.00 from $4.00. The move follows a significant plunge in Sabre's stock, which fell nearly 38% in a single day after a recent disappointing quarterly report that missed profit forecasts. However, Bernstein analysts believe the negative market reaction was overblown, stating the stock is now "oversold" and "too cheap." The firm argues that the market is incorrectly pricing in a structural decline for Sabre's core Global Distribution System (GDS) business. Bernstein sees a path for booking declines to stabilize and noted that the company has no major debt maturities until 2027, providing some financial stability. After the initial pop the shares cooled down to $1.92, up 1.6% from previous close. Is now the time to buy Sabre? Access our full analysis report here, it's free. What Is The Market Telling Us Sabre's shares are extremely volatile and have had 33 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The previous big move we wrote about was about 1 month ago when the stock dropped 4.1% on the news that the Trump administration announced intentions to impose a 35% tariff on many goods imported from Canada. This move is far more than a typical trade dispute; it targets the United States' largest and most deeply integrated trading partner. Canada is not merely a neighbor but a critical component of North American supply chains, particularly in sectors like automotive, energy, and critical minerals. This move has sparked concerns about potential retaliatory actions and a wider impact on the North American economy, leading to a risk-off sentiment among investors. The S&P 500, Dow Jones Industrial Average, and Nasdaq all opened lower, pulling back from recent record highs and heading for their first weekly loss in three weeks. Sabre is down 46.4% since the beginning of the year, and at $1.92 per share, it is trading 57.6% below its 52-week high of $4.52 from February 2025. Investors who bought $1,000 worth of Sabre's shares 5 years ago would now be looking at an investment worth $224.50. Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
19 minutes ago
- Yahoo
Why Viatris (VTRS) Stock Is Up Today
What Happened? Shares of medication company Viatris (NASDAQ:VTRS) jumped 3% in the morning session after it received approval from the U.S. Food and Drug Administration (FDA) for its Iron Sucrose Injection, USP, the first generic version of Venofer® Injection. The intravenous iron replacement product is used to treat iron deficiency anemia in adult and pediatric patients with chronic kidney disease. This approval marks a significant milestone, as it's the first generic version of Venofer®, a drug with annual U.S. sales of approximately $515 million. Crucially, the U.S. Food and Drug Administration (FDA) also granted Viatris a Competitive Generic Therapy (CGT) designation for two strengths of the drug. This designation provides Viatris with 180 days of market exclusivity, giving the company a significant first-mover advantage to capture market share for this complex-to-manufacture product. After the initial pop the shares cooled down to $9.93, up 2.3% from previous close. Is now the time to buy Viatris? Access our full analysis report here, it's free. What Is The Market Telling Us Viatris's shares are not very volatile and have only had 8 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business. The previous big move we wrote about was 24 days ago when the stock dropped 3.8% on the news that its experimental therapy for blepharitis, an inflammatory condition of the eyelids, failed to meet the main goal in a late-stage study. The global healthcare company announced that its Phase 3 trial for an ophthalmic ointment, pimecrolimus 0.3% (MR-139), did not achieve its primary endpoint. The study, which involved 477 patients, was designed to evaluate if the treatment led to the complete resolution of debris on the eyelids after six weeks of use. This outcome was not met, prompting the company to re-evaluate the future of the drug's development program. Viatris' Chief R&D Officer, Philippe Martin, stated that the company was considering its next steps, which could include revising an additional planned Phase 3 study for the therapy. The setback in the trial for this eye condition represents a disappointment for the company's pipeline. Viatris is down 20.1% since the beginning of the year, and at $9.93 per share, it is trading 25.8% below its 52-week high of $13.37 from November 2024. Investors who bought $1,000 worth of Viatris's shares 5 years ago would now be looking at an investment worth $596.45. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
19 minutes ago
- Yahoo
Why C3.ai (AI) Stock Is Trading Lower Today
What Happened? Shares of artificial intelligence (AI) software company (NYSE:AI) fell 22.6% in the afternoon session after a combination of disappointing preliminary financial results and a major leadership change. The company announced preliminary revenue for its fiscal first quarter that fell well short of analyst expectations and its own previous guidance (roughly 33% below the midpoint of its prior outlook), with CEO Thomas Siebel calling the results "completely unacceptable." Further adding to the uncertainty, Siebel is stepping down from his role due to health reasons, and the company has begun a search for a successor. This dual blow of weak performance and an unexpected leadership transition has led to multiple analyst downgrades and price target cuts, fueling a strong negative sentiment among investors. The stock's decline is a continuation of a broader struggle for the company, which has faced challenges in its growth and profitability despite the overall excitement surrounding the AI sector. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Access our full analysis report here, it's free. What Is The Market Telling Us shares are extremely volatile and have had 38 moves greater than 5% over the last year. But moves this big are rare even for and indicate this news significantly impacted the market's perception of the business. The previous big move we wrote about was 18 days ago when the stock dropped 10% on the news that the company announced it had started a search for a successor to its founder and CEO, Thomas M. Siebel. The enterprise AI software company stated that the decision followed founder and CEO Thomas M. Siebel's diagnosis with an autoimmune disease in early 2025, which led to what was described as a 'significant visual impairment.' This news introduced uncertainty regarding the company's future leadership, which weighed on investor sentiment. Siebel planned to remain in his role until a successor was appointed, after which he was set to transition to the position of Executive Chairman, focusing on strategy and customer relationships. is down 50.6% since the beginning of the year, and at $17.13 per share, it is trading 60.1% below its 52-week high of $42.94 from December 2024. Investors who bought $1,000 worth of shares at the IPO in December 2020 would now be looking at an investment worth $185.16. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.
